Knight Therapeutics Inc. (GUD.TO)
- Previous Close
5.69 - Open
5.81 - Bid 5.74 x --
- Ask 5.76 x --
- Day's Range
5.68 - 5.84 - 52 Week Range
4.35 - 5.95 - Volume
41,146 - Avg. Volume
73,477 - Market Cap (intraday)
579.704M - Beta (5Y Monthly) 0.49
- PE Ratio (TTM)
-- - EPS (TTM)
-0.16 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.73
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
www.gud-knight.com725
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: GUD.TO
Performance Overview: GUD.TO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GUD.TO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GUD.TO
Valuation Measures
Market Cap
579.71M
Enterprise Value
478.63M
Trailing P/E
--
Forward P/E
95.24
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.88
Price/Book (mrq)
0.78
Enterprise Value/Revenue
1.46
Enterprise Value/EBITDA
11.70
Financial Highlights
Profitability and Income Statement
Profit Margin
-5.13%
Return on Assets (ttm)
0.40%
Return on Equity (ttm)
-2.14%
Revenue (ttm)
328.2M
Net Income Avi to Common (ttm)
-16.84M
Diluted EPS (ttm)
-0.16
Balance Sheet and Cash Flow
Total Cash (mrq)
169.87M
Total Debt/Equity (mrq)
9.25%
Levered Free Cash Flow (ttm)
27.2M
Research Analysis: GUD.TO
Company Insights: GUD.TO
GUD.TO does not have Company Insights